PDS Biotechnology
Kirk Shepard currently serves as the Chief Medical Officer at PDS Biotechnology since January 2024. Shepard has extensive experience in medical affairs, evidenced by roles such as Board Member and Cofounder of the Medical Affairs Professional Society (MAPS) and serving as President. Prior to their current position, Shepard held senior leadership roles at EISAI LIMITED and Eisai, Inc. between March 2017 and August 2023, where responsibilities included Senior Vice President of Global Medical Affairs Oncology and Chief Medical Officer for OBG. Additionally, experience includes senior positions at Shire, Baxalta, Baxter Healthcare Corporation, and Takeda Pharmaceuticals, spanning various roles in medical and scientific affairs from 2000 to 2016. Academic credentials include an MD in Oncology and Hematology from The University of Chicago Pritzker School of Medicine and a Bachelor of Arts in Neurobiology and Behavior from Cornell University.
This person is not in any offices
PDS Biotechnology
PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers;PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers.PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.